Filtered By:
Source: International Journal of Stroke
Drug: Aspirin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 23 results found since Jan 2013.
Types of stroke recurrence in patients with ischemic stroke: A substudy from the PRoFESS trial
ConclusionsRisk predictors for stroke recurrence and for brain hemorrhage differ by index ischemic stroke subtype, information that is important when initiating secondary prevention therapy.
Source: International Journal of Stroke - October 22, 2013 Category: Neurology Authors: Danilo Toni, Emanuele Di Angelantonio, Maria Teresa Di Mascio, Richard Vinisko, Philip MW Bath, Tags: Research Source Type: research
Outcomes for people with atrial fibrillation in an Australian national audit of stroke care
ConclusionsHospital processes of care can influence outcomes in stroke patients with atrial fibrillation. The greater in‐hospital mortality experienced by stroke patients with atrial fibrillation may be attenuated by admission to a stroke unit, and for ischemic stroke, early administration of aspirin.
Source: International Journal of Stroke - July 9, 2013 Category: Neurology Authors: Nadine Andrew, Monique Kilkenny, Dawn Harris, Chris Price, Dominique A. Cadilhac Tags: Research Source Type: research
Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta‐analysis of three large randomized trials
ConclusionsUsing simple clinical variables to target aspirin to patients after acute disabling stroke by risk of thrombosis, haemorrhage or poor functional outcome does not lead to greater net clinical benefit. We suggest future risk stratification schemes include new risk factors for thrombosis and intracranial haemorrhage.
Source: International Journal of Stroke - April 12, 2015 Category: Neurology Authors: Douglas D. Thompson, Gordon D. Murray, Livia Candelise, Zhengming Chen, Peter A. G. Sandercock, William N. Whiteley Tags: Research Source Type: research
Effectiveness and safety of antiplatelet in stroke patients with end‐stage renal disease undergoing dialysis
ConclusionsAntiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end‐stage renal disease undergoing dialysis.
Source: International Journal of Stroke - February 1, 2014 Category: Neurology Authors: Chung‐Yu Chen, Kun‐Tai Lee, Charles Tzu‐Chi Lee, Wen‐Ter Lai, Yaw‐Bin Huang Tags: Research Source Type: research
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial
DiscussionPreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage is the largest secondary stroke prevention trial for informing antiplatelet therapy and lipid management in patients at high risk of haemorrhagic stroke.
Source: International Journal of Stroke - June 4, 2015 Category: Neurology Authors: Keun‐Sik Hong, Bum Joon Kim, Jun‐Young Lee, Sun U. Kwon, Tags: Protocol Source Type: research
Stroke in Bahrain: rising incidence, multiple risk factors, and suboptimal care
The incidence of stroke in Bahrain is rising in the Bahraini population and has nearly doubled over the last 16 years, while the incidence in the non‐Bahraini population has not changed. Incidence of stroke in the Bahraini population (110/100 000) is now much greater than in the non‐Bahraini population (27/100 000). The Bahraini stroke population is 10 years younger than Western comparators with a much higher prevalence of many of the risk factors for stroke, including diabetes (54%), hypertension (75%) and hyperlipidemia (34%). The combination of an ageing Bahraini population alongside a high prevalence of risk fa...
Source: International Journal of Stroke - April 1, 2015 Category: Neurology Authors: Mona Al Banna, Hassan Baldawi, Ali Kadhim, Hani Humaidan, David L. Whitford Tags: Panorama Source Type: research
The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double‐blind, placebo‐controlled multicenter trial
ConclusionThe SPAD trial is the first study to evaluate the safety and efficacy of dual antiplatelet agents, aspirin plus cilostazol, in comparison with aspirin alone in patients with both ischemic stroke or TIA and PAD. Results from this trial will provide important information on the merit of adding cilostazol to aspirin for slowing down progression of atherosclerosis in patients with ischemic stroke and PAD.
Source: International Journal of Stroke - November 14, 2014 Category: Neurology Authors: Jiann‐Shing Jeng, Yu Sun, Jiunn‐Tay Lee, Ruey‐Tay Lin, Chih‐Hung Chen, Helen L. Po, Huey‐Juan Lin, Chung‐Hsiang Liu, Ming‐Hui Sun, Mu‐Chien Sun, Chang‐Ming Chern, Li‐Ming Lien, Hou‐Chang Chiu, Han‐Hwa Hu, Hung‐Yi Chiou, Sien‐Ts Tags: Protocols Source Type: research
Effect of addition of clopidogrel to aspirin on stroke incidence: Meta‐analysis of randomized trials
ConclusionsThis meta‐analysis demonstrates a substantial relative risk reduction in stroke by clopidogrel plus aspirin vs. aspirin alone that is consistent across different trial cohorts. Major haemorrhage is increased by dual antiplatelet therapy.
Source: International Journal of Stroke - May 22, 2013 Category: Neurology Authors: Santiago Palacio, Robert G. Hart, Lesly A. Pearce, David C. Anderson, Mukul Sharma, Lee A. Birnbaum, Oscar R. Benavente Tags: Research Source Type: research
Platelet‐Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design
DiscussionAspirin is the most common antithrombotic given to patients with a stroke or transient ischemic attack, as it reduces the risk of subsequent stroke. This trial expects to determine whether more aggressive antithrombotic therapy with clopidogrel plus aspirin, initiated acutely, is more effective than aspirin alone.
Source: International Journal of Stroke - July 23, 2013 Category: Neurology Authors: S. Claiborne Johnston, J. Donald Easton, Mary Farrant, William Barsan, Holly Battenhouse, Robin Conwit, Catherine Dillon, Jordan Elm, Anne Lindblad, Lewis Morgenstern, Sharon N. Poisson, Yuko Palesch Tags: Protocols Source Type: research
Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study
ConclusionsEarly dual therapy with clopidogrel and aspirin reduces microembolic signals in patients with minor ischemic stroke or transient ischemic attack, without causing significant bleeding complications.
Source: International Journal of Stroke - March 12, 2013 Category: Neurology Authors: Alexander Y. Lau, Yudong Zhao, Christopher Chen, Thomas W. Leung, Jianhui Fu, Yining Huang, Nijasri C. Suwanwela, Zhao Han, Kay Sin Tan, Disya Ratanakorn, Hugh S. Markus, Ka Sing Wong, Tags: Clinical Trial Source Type: research
Differences in ischemic and hemorrhagic recurrence rates among race‐ethnic groups in the PRoFESS secondary stroke prevention trial
ConclusionsWe found a significant difference in myocardial infarction and symptomatic intracerebral hemorrhage recurrence among different race‐ethnic groups. The risk of recurrent ischemic and hemorrhagic stroke was greater in Asians with high blood pressure.
Source: International Journal of Stroke - March 18, 2014 Category: Neurology Authors: Conrado J. Estol, Philip M. W. Bath, Philip B. Gorelick, Daniel Cotton, Renee Hebert Martin, Tags: Research Source Type: research
Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation
DiscussionThe results of this proof‐of‐concept trial will guide go/no‐go decision to a large phase 3 confirmatory trial.
Source: International Journal of Stroke - October 26, 2014 Category: Neurology Authors: Keun‐Sik Hong, Yun Jung Choi, Sun U. Kwon, Tags: Protocols Source Type: research
Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)
DiscussionThe trial has recruited more than 50% of its target sample size (latest number: 2399) and is running in 104 sites in 4 countries. One‐third of patients presented with a transient ischemic attack.
Source: International Journal of Stroke - June 16, 2015 Category: Neurology Tags: Protocol Source Type: research
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design
DiscussionThe SOCRATES trial fulfills an important clinical need by evaluating a potent antiplatelet agent as a superior alternative to current standard of care in patients presenting acutely with ischemic stroke or transient ischemic attack.
Source: International Journal of Stroke - August 26, 2015 Category: Neurology Authors: S. Claiborne Johnston, Pierre Amarenco, Gregory W. Albers, Hans Denison, J. Donald Easton, Peter Held, Jenny Jonasson, Kazuo Minematsu, Carlos A. Molina, Lawrence K. S. Wong Tags: Protocol Source Type: research
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open‐label, parallel‐group trial
DiscussionThe CSPS.com is expected to provide evidence indicating whether secondary IS prevention in high‐risk patients can be improved by using DAPT involving cilostazol.
Source: International Journal of Stroke - December 8, 2014 Category: Neurology Authors: Kazunori Toyoda, Shinichiro Uchiyama, Haruhiko Hoshino, Kazumi Kimura, Hideki Origasa, Hiroaki Naritomi, Kazuo Minematsu, Takenori Yamaguchi, Tags: Protocols Source Type: research
